Immucell Overview
Immucell (ICCC) has a P/E ratio of 117.61, above the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow117.61
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for ICCC is 117.61. That is above the Healthcare sector average of 25.3. Investors often review this figure alongside Immucell's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ICCC currently prints 117.61 for P/E ratio, while the sector average sits near 25.3. That is roughly 365.0% above the sector mean. Large gaps often invite a closer look at Immucell's growth, margins, and balance sheet.
A P/E ratio of 117.61 for Immucell is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with ICCC's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ICCC's P/E ratio (117.61), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Immucell's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
